Down on luck, Lilly finds comfort in pets
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
Life Science & Biotech
Articles
Endocyte prices IPO stock
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
Panel says Lilly’s Solpura isn’t ready for approval
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
UPDATE: Judge adds probation to Guidant device plea deal
A Minnesota judge has signed off on a plea agreement that calls for Boston Scientific Corp.'s Guidant unit to pay $296 million for failing to properly disclose changes made to some implantable heart devices, but added three years of probation to the deal.
Roche back in court as partner looks to sell to competitor
Roche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving word the company is speeding up plans to sell itself to Roche rival Alere Inc.
Guidant to appear in federal court for sentencing
Boston Scientific Corp.'s Guidant unit hopes to end a criminal case accusing it of failing to properly disclose changes made to some implantable heart devices when it appears in court Wednesday.
Deal could give Lilly full diabetes deck
Eli Lilly and Co.’s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
UPDATE: Analysts praise Lilly diabetes deal with Boehringer
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
Roche aims to prevent bidding war for software firm
The Swiss company, which operates its North American business out of Indianapolis, filed a lawsuit late last month against Virginia-based Medical Automation Systems Inc. for breaching the purchase agreement the companies signed back in October.
Aprimo sale may usher in ‘new wave’ of tech deals
Observers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not only among IT firms, but also among biotech companies here.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Indiana Seed Fund makes 11th investment
A $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development stage.
Lilly Alzheimer’s imaging agent to get priority FDA review
Eli Lilly and Co. said the Food and Drug Administration will perform a faster review of florbetapir, an imaging agent that may help diagnose Alzheimer's disease.
Zimmer looks to China to reignite growth
Zimmer Holdings Inc. completed an acquisition in China on Tuesday, but recession hangovers in the United States and Europe are trumping all other factors and keeping the company’s growth bottled up for now.
Lilly Endowment gives $35M to start pharmacy school
Manchester College will use money to launch the state’s third program offering doctorates in pharmacy.
Biomet owners look to arrange $11B marriage
Warsaw-based Biomet Inc. could get a whole lot bigger if rumors prove true that its owners have made a bid for U.K.-based rival Smith & Nephew plc.
State adds record number of life sciences jobs
Twenty companies committed this year to add more than 4,000 jobs.
Dow AgroSciences moves into new research facility
The division of Dow Chemical has a 15-year lease with Indianapolis-based developer Browning Investments on the two-story building near West 96th Street.
Medical device maker expanding in Fort Wayne
L.H. Medical Corp. said it plans to create up to 65 jobs by 2013 and invest $5.4 million to more than triple the size of its manufacturing operations.